Chronic kidney disease in gout in a managed care setting

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Fuldeore, Mahesh J ^a   Riedel, Aylin A ^b   Zarotsky, Victoria ^b   Pandya, Bhavik J ^c   Dabbous, Omar ^c   Krishnan, Eswar ^d  

^a ABBOTT LABORATORIES   (United States)

^b OPTUM   (United States)

^c Takeda Pharmaceuticals International Inc   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; URIC ACID; ANTIGOUT AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE TITRATION; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; SEX RATIO; URIC ACID BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FOLLOW UP; HEALTH INSURANCE; MIDDLE AGED;

ADULT; AGED; ALLOPURINOL; FEMALE; FOLLOW-UP STUDIES; GOUT; GOUT SUPPRESSANTS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; URIC ACID;

EID: 79960995406     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-36     Document Type: Article

References (35)

1. New insights into gout epidemiology. TR Mikuls, KG Saag, Curr Opin Rheumatol 2006 18 199 203 10.1097/01.bor.0000209435.89720.7c 16462529 (Pubitemid 43740396)
2. Gout in ambulatory care settings in the United States. E Krishnan, D Lienesch, CK Kwoh, J Rheumatol 2008 35 498 501 18260174 (Pubitemid 351374428)
3. Prevalence of chronic kidney disease in the United States. J Coresh, E Selvin, LA Stevens, J Manzi, JW Kusak, P Eggers, F Van Lente, AS Levey, JAMA 2007 298 2038 47 10.1001/jama.298.17.2038 17986697 (Pubitemid 350074801)
4. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. KL Wallace, AA Riedel, N Joseph-Ridge, R Wortmann, J Rheumatol 2004 31 1582 7 15290739 (Pubitemid 39006641)
5. Gout: epidemiology and lifestyle choices. HK Choi, G Curhan, Curr Opin Rheumatol 2005 17 341 5 15838248 (Pubitemid 40616583)
6. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. A Shoji, H Yamanaka, N Kamatani, Arthritis Rheum 2004 51 321 325 10.1002/art.20405 15188314 (Pubitemid 38725128)
7. Hyperuricaemia - where nephrology meets rheumatology. Z Avram, E Krishnan, Rheumatology (Oxford) 2008 47 960 964 10.1093/rheumatology/ken070 (Pubitemid 351865915)
8. Disease-related and all-cause health care costs of elderly patients with gout. EQ Wu, PA Patel, AP Yu, RR Mody, KE Cahill, J Tang, E Krishnan, J Manag Care Pharm 2008 14 164 75 18331118 (Pubitemid 351453817)
9. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. KR Hande, RM Noone, WJ Stone, Am J Med 1984 76 47 56 6430077 (Pubitemid 14216359)
10. Relationship of uric acid with progression of kidney disease. M Chonchol, MG Shlipak, R Katz, MJ Sarnak, AB Newman, DS Siscovick, B Kestenbaum, JK Carney, LF Fried, Am J Kidney Dis 2007 50 239 47 10.1053/j.ajkd.2007.05.013 17660025 (Pubitemid 47095076)
11. Uric acid and incident kidney disease in the community. DE Weiner, H Tighiouart, EF Elsayed, JL Griffith, DN Salem, AS Levey, J Am Soc Nephrol 2008 19 1204 11 10.1681/ASN.2007101075 18337481
12. Allopurinol treatment and its effect on renal function in gout: a controlled study. T Gibson, V Rodgers, C Potter, HA Simmonds, Ann Rheum Dis 1982 41 59 65 10.1136/ard.41.1.59 7039523 (Pubitemid 12136653)
13. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. F Perez-Ruiz, M Calabozo, AM Herrero-Beites, G García-Erauskin, JI Pijoan, Nephron 2000 86 287 91 10.1159/000045783 11096285
14. Factors associated with musculoskeletal disability, and chronic renal failure in clinically diagnosed primary gout. J Alvarez-Nemegyei, JC Cen-Piste, M Medina-Escobedo, S Villanueva-Jorge, J Rheumatol 2005 32 1923 7 16206348 (Pubitemid 41430484)
15. Gout due to renal disease. PC Vecchio, BT Emmerson, Br J Rheumatol 1992 31 63 5 10.1093/rheumatology/31.1.63 1730109
16. Association of incident gout and mortality in dialysis patients. SD Cohen, PL Kimmel, R Neff, L Agodoa, KC Abbott, J Am Soc Nephrol 2008 19 2204 10 10.1681/ASN.2007111256 18508965
17. Hyperuricemia and gout following pediatric renal transplantation. G Sparta, MJ Kemper, TJ Neuhaus, Pediatr Nephrol 2006 21 1884 8 10.1007/s00467-006-0257-5 16947031 (Pubitemid 44741168)
18. Gout in renal transplant recipients. L Stamp, L Ha, M Searle, J O'Donnel, C Frampton, P Chapman, Nephrology (Carlton) 2006 11 367 71 10.1111/j.1440-1797. 2006.00577.x (Pubitemid 44086883)
19. Preliminary criteria for the classification of the acute arthritis of primary gout. SL Wallace, H Robinson, AT Masi, JL Decker, DJ McCarty, TF Yü Arthritis Rheum 1977 20 895 900 10.1002/art.1780200320 856219
20. Validity of gout diagnoses in administrative data. LR Harrold, KG Saag, RA Yood, TR Mikuls, SE Andrade, H Fouayzi, J Davis, KA Chan, MA Raebel, A Von Worley, R Platt, Arthritis Rheum 2007 57 103 8 10.1002/art.22474 17266097
21. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. AS Levey, JP Bosch, JB Lewis, T Greene, N Rogers, D Roth, Ann Intern Med 1999 130 461 70 10075613 (Pubitemid 29135798)
22. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). W Zhang, M Doherty, T Bardin, E Pascual, V Barskova, P Conaghan, J Gerster, J Jacobs, B Leeb, F Liot, G McCarthy, P Netter, G Nuki, F Perez-Ruiz, A Pignone, OJ Piment, L Punzi, E Roddy, T Uhlig, I Zimmerman-Gárska, Ann Rheum Dis 2006 65 1312 24 10.1136/ard.2006.055269 16707532 (Pubitemid 44620440)
23. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. ME Charlson, P Pompei, KL Ales, CR MacKenzie, J Chronic Dis 1987 40 373 83 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
24. Comorbidity measures for use with administrative data. A Elixhauser, C Steiner, DR Harris, RM Coffey, Med Care 1998 36 8 27 10.1097/00005650-199801000- 00004 9431328 (Pubitemid 128456396)
25. A survey of indications, results and complications of surgery for tophaceous gout. S Kumar, P Gow, N Z Med J 2002 115 109 12362184
26. Product Monograph: Zyloprim, allopurinol tablets USP. Anonymous, Mississauga, ON, Canada 2006
27. Appropriate dosing regimen of allopurinol in Japanese patients. M Takada, H Okada, T Kotake, N Kawato, M Saito, M Nakai, T Gunji, M Shibakawa, J Clin Pharm Ther 2005 30 407 12 10.1111/j.1365-2710.2005.00670.x 15985055 (Pubitemid 41603039)
28. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. F Perez-Ruiz, I Hernando, I Villar, JM Nolla, J Clin Rheumatol 2005 11 129 33 10.1097/01.rhu.0000164822.98163.22 16357730 (Pubitemid 40863823)
29. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. N Dalbeth, S Kumar, L Stamp, P Gow, J Rheumatol 2006 33 1646 50 16783857 (Pubitemid 44168841)
30. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. L Stamp, P Gow, K Sharples, B Raill, Aust N Z J Med 2000 30 567 72 11108066
31. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. M Bigby, S Jick, H Jick, K Arndt, JAMA 1986 256 3358 63 10.1001/jama.256.24.3358 2946876 (Pubitemid 17201796)
32. Incidence of allopurinol hypersensitivity syndrome (AHS) among renally impaired patients [abstract]. D Khanna, BJ Pandya, AO D'Souza, BL Meissner, R Kamalaker, V Harikrishnan, Arthritis Rheum 2009 60 Suppl 10 2043
33. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. LK Stamp, JL O'Donnell, M Zhang, J James, C Frampton, ML Barclay, PT Chapman, Arthritis Rheum 2011 63 412 21 10.1002/art.30119 21279998
34. Relation between adverse events associated with allopurinol and renal function in patients with gout. J Vázquez-Mellado, EM Morales, C Pacheco-Tena, R Burgos-Vargas, Ann Rheum Dis 2001 60 981 3 10.1136/ard.60.10.981 11557658 (Pubitemid 32885676)
35. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. SI Hung, WH Chung, LB Liou, CC Chu, M Lin, HP Huang, YL Lin, JL Lan, LC Yang, HS Hong, MJ Chen, PC Lai, JY Wu, YT Chen, Proc Natl Acad Sci 2005 102 4134 9 10.1073/pnas.0409500102 15743917 (Pubitemid 40388568)